ADMA News and Press, ADMA Biologics Inc From 04/18/22

Institutional ownership has grown in the past 6 months. An activist investor is watching ADMA intently. ADMA's Q4 report was very promising. For further details see: ADMA: Pertinent Updates

3 Penny Stocks For Your Watchlist After a Bearish Trading Day There’s a lot of debate surrounding penny stocks – whether they’re actually worth investing in, or if they’re just an easy way to make quick money. So, what’s the verdict? Are penny stocks...

RAMSEY, N.J. and BOCA RATON, Fla., April 01, 2022 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA” or the “Company”), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived b...

ADMA reported full-year 2021 numbers on March 24, which disclosed higher than expected revenue, a lower than expected net loss, and strong 2022 guidance. ADMA has been investing heavily in a vertically integrated business model for years, and we are now starting to see those increased...

3 Penny Stocks to Add to Your Watchlist in April There is no simple answer to the question of whether penny stocks are a good investment or not. It depends on a variety of factors, including the current state of the economy, the company’s financial stability, and your own persona...

ADMA Biologics (NASDAQ:ADMA) said the U.S. Food and Drug Administration (FDA) approved to extend the expiration dating to 36 months from 24 months for its Asceniv and Bivigam immune globulin (IG) drug product stored at 2-8°C. The company said the expiration date extension applies to all ...

Approval of 36-month shelf life encompasses all ASCENIV & BIVIGAM vial sizes, production scales, as well as internal and external fill-finishing Extended shelf life ASCENIV & BIVIGAM now commercially available to U.S. healthcare providers RAMSEY, N.J. and BOCA RATO...

Shares of ADMA Biologics (NASDAQ:ADMA) are up 2% in after-hours trading after the company's Q4 2021 results beat on both the top and bottom lines. The company is also guiding full-year 2022 revenue of more than $125M, which would be more than 50% year-over-year growth. ADMA's (ADMA)...

ADMA Biologics press release (NASDAQ:ADMA): Q4 GAAP EPS of -$0.09 beats by $0.01. Revenue of $26.38M (+89.0% Y/Y) beats by $4.61M. Shares +3.3%. For further details see: ADMA Biologics GAAP EPS of -$0.09 beats by $0.01, revenue of $26.38M beats by $4.61M

Full Year 2021 Total Revenues of Approximately $81 Million, a 92% Increase Over Full Year 2020 Gross Profitability for Full Year 2021 Driven by Greater Market Penetration of Higher-Margin Product Mix Completed $175 Million Debt Refinancing with Hayfin Capital Management,...